Skip to content
zameds
Loading the molecular structure
C33H35FN2O5558.60 g/mol

(3R,5R)-7-[2-(4-Fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid

Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 60823.

Registration

Applicants
1
Registrations
4

Applicants and registrations

ApplicantBrandsDosagesRegistrationsScheduleLeaflets
Ranbaxy Pharmaceutical (Pty) LtdAtorvastatin sun10, 20, 40, 80420552, 420553, 420554, 420555Not determinedNone

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Atorvastatin sun 10

EACH TABLET CONTAINS ATORVASTATIN 10,0 mg

1042055242/7.5/0552RegisteredNot determinedNone
Atorvastatin sun 20

EACH TABLET CONTAINS ATORVASTATIN 20,0 mg

2042055342/7.5/0553RegisteredNot determinedNone
Atorvastatin sun 40

EACH TABLET CONTAINS ATORVASTATIN 40,0 mg

4042055442/7.5/0554RegisteredNot determinedNone
Atorvastatin sun 80

EACH TABLET CONTAINS ATORVASTATIN 80,0 mg

8042055542/7.5/0555RegisteredNot determinedNone

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S4: Atorvastatin

    Consolidated Schedules 06 July 2026, line 5376

  • S4: Ezetimibe

    Consolidated Schedules 06 July 2026, line 6302

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

Background

Loading...
Loading Wikipedia summary

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Research articles

Loading...
Loading PubMed articles